Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03878693 · ClinicalTrials.gov registry record · Early Phase 1

4-methylpyrazole and Acetaminophen Metabolism

A Early Phase 1 study of Healthy Adult Volunteers, sponsored by University of Arizona.

Completed
Registry status
Early Phase 1
Development phase
6
Enrollment target
1
Study location

NCT03878693 is a Early Phase 1 study of Healthy Adult Volunteers that has completed, run by University of Arizona. The registered enrollment target is 6 participants, below the 22-participant average among 4 other Healthy Adult Volunteers trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03878693, a Early Phase 1 study of Healthy Adult Volunteers, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
Early Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

Oxidative metabolism of APAP will be studied with and without 4-MP.

Conditions Studied

Interventions

  • DRUG Fomepizole
  • DRUG APAP

Study Locations (1)

Arizona

  • BUMCP - Department of Medical Toxicology - Phoenix

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2018-07-01
Est. Completion 2018-10-31
Phase Early Phase 1

Sponsor

University of Arizona

349 total trials

What the Registry Record Tells You About NCT03878693

The ClinicalTrials.gov registry entry for NCT03878693 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 22-participant average among 4 other Healthy Adult Volunteers trials with a reported enrollment target (73% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adult Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Fomepizole is the first listed.

NCT03878693 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT03878693 about?

NCT03878693 is a clinical study titled "4-methylpyrazole and Acetaminophen Metabolism". Oxidative metabolism of APAP will be studied with and without 4-MP.

What is the current status of trial NCT03878693?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2018-07-01. Estimated completion is 2018-10-31.

What conditions does trial NCT03878693 study?

This clinical trial studies the following conditions: Healthy Adult Volunteers.

What interventions are being tested in trial NCT03878693?

The interventions under investigation include: Fomepizole (DRUG), APAP (DRUG).

Who is sponsoring clinical trial NCT03878693?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03878693 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.